Barinthus Biotherapeutics (BRNS) Cash & Current Investments (2020 - 2026)

Barinthus Biotherapeutics has reported Cash & Current Investments for 7 years, with the latest figure at $67.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments fell 33.2% year-over-year to $67.2 million; the trailing twelve-month figure through Mar 2026 stood at $67.2 million (down 33.2% YoY), and the FY2025 full-year result was $71.9 million, down 36.07% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $67.2 million, down from $71.9 million in the prior quarter.
• The five-year high for Cash & Current Investments was $200.6 million in Q1 2022, with the low at $67.2 million in Q1 2026.
• Historically, Cash & Current Investments has averaged $136.3 million across 5 years, with a median of $123.9 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Current Investments advanced 28.64% — and 2025, when it plunged 36.07%.
• Barinthus Biotherapeutics' Cash & Current Investments stood at $194.4 million in 2022, then retreated by 17.53% to $160.3 million in 2023, then retreated by 29.89% to $112.4 million in 2024, then sank by 36.07% to $71.9 million in 2025, then fell by 6.49% to $67.2 million in 2026.
• The last three Cash & Current Investments figures came in at $67.2 million (Q1 2026), $71.9 million (Q4 2025), and $75.7 million (Q3 2025), per Business Quant data.